NCT05186753 ACTIVE NOT RECRUITING (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cogent Biosciences, Inc.
NCT03731260 ACTIVE NOT RECRUITING (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
NCT04996875 RECRUITING (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Cogent Biosciences, Inc.
NCT04655118 RECRUITING Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
Telios Pharma, Inc.
NCT03580655 COMPLETED (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation
NCT03770273 COMPLETED Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03214666 TERMINATED GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
GT Biopharma, Inc.
NCT03739606 WITHDRAWN Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
City of Hope Medical Center
NCT02415608 TERMINATED Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
Jason Robert Gotlib
NCT02478957 COMPLETED Treatment of Indolent Systemic Mastocytosis With PA101
Patara Pharma